Arndt Vogel· @ArndtVogel · X·· 2 天前评分90
正文 · 原文
Zanidatamab + CT ± tislelizumab for 1L HER2-positive mGEA: Second IA from HERIZON-GEA-01
#ESMO26 #ESMOAmbassadors
👉 mOS: 27 vs22.9 vs 19.6 mo
🧐Continued meaningful benefit for Zani & Tis independent of PDL-1
@myESMO @ASCO
812 浏览 · 12 赞 · 9 转发 · 0 回复
会议摘要
LBA79按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Zanidatamab (zani) + chemotherapy (CT) ± tislelizumab (TIS) for first-line (1L) HER2-positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (mGEA): Second interim analysis (IA) from HERIZON-GEA-01
https://esmocongress.esmo.org来源：Arndt Vogel · x.com